Grant ID RP110508
Awarded On March 24, 2011
Title Clinical Development of CaspaCIDe, a Cell Therapy Safety Switch
Program Product Development Research
Award Mechanism Company Commercialization
Institution/Organization Bellicum Pharmaceuticals, Inc.
Principal Investigator/Program Director Kevin Slawin
Cancer Sites Leukemia, Lymphoma, Myeloma
Contracted Amount $5,680,310
Lay Summary

Many leukemia and lymphoma patients, including children and adults, are cured by a bone marrow transplant. However, cancer relapse, infection and GvHD are common in the months after a transplant. They cause suffering for the patient, are very difficult and expensive to manage, and are fatal for 30-50% of patients.

The problem is that harmful T cells in the transplant cannot be separated from essential, helpful T cells. These helpful T cells are better at eliminating residual cancer cells than the patient’s own T cells, they help the donor bone marrow cells become established, and they control infections that previously lay dormant. The harmful T cells cause GvHD by attacking the skin, the in...

Read More